Physicians' Academy for Cardiovascular Education

HDL-c in CV disease

3' education - July 1, 2011

HDL cholesterol:
Current and future opportunities for the reduction of cardiovascular disease

Prof. Phil Barter, Sydney, Australia in discussion with prof John Kastelein on the current and future opportunities for managing HDL cholesterol in the reduction of cardiovascular disease.

Questions to be addressed in this PACE expert opinion are:
  • HDL Cholesterol as therapeutic target: What are your hopes for the future in terms of CVD reduction?
  • HDL Cholesterol: What are the therapeutic options
  • HDL Cholesterol and CETP inhibitors: What are the developments?
  • HDL Cholesterol and therapeutic options: Will we be able to manage the entire lipoprotein profile?

View prof Kastelein in discusion with prof Barter

About the speakers

Professor Philip Barter
Director, The Heart Research Institute,
Professor of Medicine, University of Sydney, Sydney, Australia

Professor Barter is President-Elect of the ISA. Professor Barter’s basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins. His clinical research involves participation in clinical trials. He was a member of the steering committees of the FIELD study and of the TNT Study and was chairman of the steering committee of the ILLUMINATE study. He is currently a member of the steering committee of the DalOutcomes and is co-chair of the DEFINE trial; these are studies of new CETP inhibitors.

Professor  John Kastelein
Professor of Medicine
Chairman, Department of Vascular Medicine, University of Amsterdam, The Netherlands

Prof Kastelein’s current research interests are in the aetiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. Recently Dr. Kastelein has developed the use of non-invasive B-mode ultrasound studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis.

More about HDL cholesterol

Clinical and epidemiologic studies have consistently shown that low levels of high-density lipoprotein (HDL) cholesterol are strongly associated with an increase in the risk of coronary artery disease. Despite the abundant evidence for the inverse association between HDL cholesterol and the risk of coronary disease, certain drugs, such as fibric acid derivatives, that elevate HDL cholesterol levels show inconsistent clinical benefit. It is unclear how HDL in humans interacts with the artery wall to influence the progression or regression of atherosclerosis.A central hypothesis is that HDL promotes cholesterol efflux from macrophage foam cells in atheromatous vessels decreasing the cholesterol burden and macrophage-driven inflammation.

View the Powerpoint slides presented

Slide 1

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: